Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	Unknown
Gender:	Unknown
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Purkinje Cell Antibody, Titer, CSF (Do NOT give this test code to clients - Panel Component ONLY. Refer to 2010841.)
ARUP test code 2010845

Purkinje Cell Antibody Titer IgG, CSF   **1:20   ***   (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: Purkinje Cell Antibody Titer IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Paraneoplastic Reflexive Panel, CSF
ARUP test code 3004517

Paraneoplastic Abs (PCCA/ANNA) IgG, CSF   **PCCA Detected   ***   (Ref Interval: None Detected)

 Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

INTERPRETIVE INFORMATION: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CV2 Ab IgG CBA-IFA Screen, CSF   **Detected   ***   (Ref Interval: < 1:1)

CV2 Antibody, IgG is detected. Titer results to follow.
Additional charges apply.

H=High, L=Low, *=Abnormal, C=Critical

Patient: Patient, Example
ARUP Accession: 24-057-100495
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 4 | Printed: 2/26/2024 11:10:17 AM
4848

ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Screen, CSF

CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

SOX1 Antibody, IgG by Immunoblot, CSF

High Positive   *   (Ref Interval: Negative)

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, CSF

SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Amphiphysin Antibody, CSF

Positive   *   (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Amphiphysin Antibody IgG, CSF

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CV2 Antibody Titer, IgG by CBA-IFA, CSF (Reflex for 3017001 CV2 CSF - Not orderable by clients)
ARUP test code 3017002

CV2 Ab IgG CBA-IFA Titer, CSF   1:20   *   (Ref Interval: < 1:1)

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-057-100495
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 4 | Printed: 2/26/2024 11:10:17 AM
4848

800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Report |**FINAL**

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot, CSF
ARUP test code 3004527

Neuronal Nuclear Ab (Hu) IgG, IB, CSF	**Positive**	*****	**(Ref Interval: Negative)**

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Hu) IgG, IB, CSF
This test detects IgG antineuronal antibodies to Hu, Ri, and Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (Ri) IgG, IB, CSF	**High Positive**	*****	**(Ref Interval: Negative)**

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, CSF
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (Yo) IgG, IB, CSF	**Positive**	*****	**(Ref Interval: Negative)**

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, CSF
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (TR/DNER) IgG, CSF	**High Positive**	*****	**(Ref Interval: Negative)**

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-057-100495
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 4 | Printed: 2/26/2024 11:10:17 AM
4848

ARUP
LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Report |**FINAL**

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (TR/DNER)
IgG, CSF
This test was developed and its performance characteristics
determined by ARUP Laboratories. It has not been cleared or
approved by the US Food and Drug Administration. This test was
performed in a CLIA certified laboratory and is intended for
clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Purkinje Cell Antibody Titer IgG, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2 Ab IgG CBA-IFA Screen, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2 Ab IgG CBA-IFA Titer, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SOX1 Antibody, IgG by Immunoblot, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Hu) IgG, IB, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Ri) IgG, IB, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Yo) IgG, IB, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Amphiphysin Antibody, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (TR/DNER) IgG, CSF	24-057-100495	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:
ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-057-100495
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 4 of 4 | Printed: 2/26/2024 11:10:17 AM
4848